

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## 首長國際企業有限公司

**SHOUGANG CONCORD INTERNATIONAL ENTERPRISES COMPANY LIMITED**  
(Incorporated in Hong Kong with limited liability)

(Stock Code: 697)

### **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE OF COMPOSITION OF BOARD COMMITTEES**

The Board is pleased to announce that Dr. Qiao Yongyuan has been appointed as an Independent Non-executive Director and a member of each of the Audit Committee and the Remuneration Committee of the Company with effect from 14 June 2019.

#### **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE OF COMPOSITION OF BOARD COMMITTEES**

The board of directors (the “**Board**”) of Shougang Concord International Enterprises Company Limited (the “**Company**”) is pleased to announce that Dr. Qiao Yongyuan has been appointed as an Independent Non-executive Director and a member of each of the Audit Committee and the Remuneration Committee of the Company with effect from 14 June 2019.

**Dr. Qiao Yongyuan** (“**Dr. Qiao**”), aged 36, obtained a Bachelor degree in Physics from Peking University in the People’s Republic of China in 2005 and a Doctorate degree in Philosophy from the University of St Andrews in the United Kingdom in 2008. He currently works in Industrial Bank Co., Ltd. as the chief strategist and worked in Guotai Junan Securities Co., Ltd., a company listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), where he was the chief strategy analyst who led the strategy research team. Dr. Qiao also served as a consultant for each of China Soong Ching Ling Foundation and China Youth Development Foundation. He received the first prize and the second prize for the “Best Strategic Analyst” awarded by New Fortune in October 2015 and October 2014, respectively. Dr. Qiao also received the second prize for the “Crystal Ball Award for Best Strategic Analyst” awarded by Security Market Weekly for two consecutive years from 2014 to 2015. He has extensive experience in financial management and securities trading.

Dr. Qiao will enter into an engagement letter with the Company for a term commencing from 14 June 2019 and ending on 31 December 2019, subject to retirement and re-election at the next following annual general meeting and thereafter subject to retirement by rotation and re-election at least once every three years at annual general meetings of the Company in accordance with the articles of association of the Company. Pursuant to the engagement letter, Dr. Qiao is entitled to a director’s fee as may be determined by the Board from time to time pursuant to the authority given by the shareholders of the Company and yet Dr. Qiao confirmed that he opted not to receive any director’s fee during his engagement.

Save as disclosed above, Dr. Qiao did not hold any directorships in other Hong Kong or overseas listed public companies in the last three years, does not hold other positions in the Company or its subsidiaries and does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)).

As at the date of this announcement and within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), Dr. Qiao does not have any interests in the shares of the Company.

Save as set out above, there is no other matter regarding the appointment of Dr. Qiao that needs to be brought to the attention of the shareholders of the Company and there is no other information that needs to be disclosed pursuant to the requirements of Rules 13.51(2) of the Listing Rules.

The Board would like to take this opportunity to welcome Dr. Qiao to join the Board.

By order of the Board  
**Shougang Concord International  
Enterprises Company Limited**  
**Zhao Tianyang**  
*Chairman*

Hong Kong, 13 June 2019

*As at the date of this announcement, the Board comprises Mr. Zhao Tianyang (Chairman), Mr. Li Shaofeng (Vice Chairman), Mr. Xu Liang and Mr. Liang Hengyi (Managing Director) as Executive Directors; Dr. Li Yinhui, Mr. Liu Jingwei, Mr. Ho Gilbert Chi Hang and Mr. Li Hao as Non-executive Directors; Dr. Wang Xin, Mr. Choi Fan Keung Vic, Mr. Deng Yougao and Ms. Zhang Quanling as Independent Non-executive Directors.*